Clinical trials: completed, sponsored by Dana-Farber Cancer Institute
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Drug/Agent Toxicity by Tissue/Organ, Leukemia
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis.
- Trial name
- NCT00400946
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Cancer, CNS Tumor, Childhood
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.
- Conditions
- Pediatric Cancer, CNS Tumor, Childhood, Skin Inflammation
- Trial name
- NCT04479514
- Testing
- Warm Baths or Showers, Moisturizer, SPF 30 or Higher Suncreen
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Acute Lymphoblastic Leukemia, Leukemia
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
The goal of this research study is to understand the acceptability and feasibility of the Sleep ALL Night intervention among children with Acute Lymphoblastic Leukemia (ALL) in hopes of improving the discussion of sleep disorders…
- Conditions
- Pediatric Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05866887
- Testing
- Sleep ALL Night
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Brain Tumor
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia.
- Conditions
- Leukemia, Brain Tumor, Solid Tumor, Lymphoma
- Trial name
- NCT03654716
- Testing
- ALRN-6924, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumor, Childhood, Lymphoma
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma.
- Conditions
- Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric
- Trial name
- NCT03936465
- Testing
- BMS-986158, BMS-986378
- Where
- 6 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Dana-Farber Cancer Institute
Other Cancer
Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention
The goal of this new intervention is to make it easier for families to meet their basic household needs during childhood cancer treatment. The investigators want to learn how to best use PediCARE to help care for families.
- Trial name
- NCT03638453
- Testing
- PediCARE, Usual Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Bone Mineral Density, Childhood Cancer Survivors
Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
This research study is evaluating bone mineral density in childhood cancer survivors who have a history of bone fracture.
- Trial name
- NCT02355340
- Testing
- Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
Laboratory and other studies suggest that, the study drug, Everolimus (RAD001), may prevent tumor cell growth and also may increase the efficacy of other chemotherapy drugs.
- Trial name
- CRAD001NUS175T (NCT01523977)
- Testing
- Everolimus, Prednisone, Vincristine
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease
Gut Decontamination In Pediatric Allogeneic Hematopoietic
This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD).
- Trial name
- NCT02641236
- Testing
- Vancomycin-polymyxin B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Cabozantinib With Topotecan-Cyclophosphamide
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma.
- Conditions
- Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT04661852
- Testing
- Cabozantinib, Topotecan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Sleep Problem, Insomnia
Survivor-Sleep Health Information Program
The purpose of the study is to learn if an educational program delivered to parents/guardians can help improve the sleep of children experiencing sleep problems after completing cancer treatment.
- Conditions
- Sleep Problem, Insomnia, Pediatric Cancer
- Trial name
- NCT04863157
- Testing
- Survivor-SHIP
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Anxiety, Oncology
Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer
This study is evaluating how well a music therapy program works to improve anxiety and stress in adolescents and young adults receiving cancer treatment.
- Conditions
- Anxiety, Oncology, Stress
- Trial name
- MAYA (NCT03709225)
- Testing
- Music-based meditation
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Dana-Farber Cancer Institute
Nonmalignant Neoplasm, Tuberous Sclerosis
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM.
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Trial name
- NCT00126672
- Testing
- Rapamycin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
The purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), will delay or stop the growth of the…
- Conditions
- Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT00258687
- Testing
- GVAX
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Insomnia
Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors
This research study is evaluating a six-session online program designed to help insomnia (difficulty falling or staying asleep) in adolescent and young adult cancer survivors.
- Trial name
- NCT03279055
- Testing
- SHUTi
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Versus Graft Host Disease
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
This research study is a way of gaining new knowledge about the treatment for cGVHD that has not responded to steroids. This research study is evaluating a drug called Interleukin-2 (IL-2) as a possible treatment for cGVHD.
- Trial name
- NCT02318082
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Myelodysplastic Syndromes
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00376480
- Testing
- anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Glioma, Low-grade Glioma
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas. Additionally, the safety of RAD001 will be studied.
- Conditions
- Glioma, Low-grade Glioma, Astrocytoma
- Trial name
- NCT00782626
- Testing
- everolimus
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute